Title: Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferative disease in mice via altered *Runx1* splicing

Authors: Marisa J. L. Aitken^{1,2*}, Purna Malaney^{1*}, Xiaorui Zhang¹, Shelley M. Herbrich^{1,2}, Lauren Chan¹, Huaxian Ma¹, Rodrigo Jacamo¹, Ruizhi Duan^{3,4}, Todd M. Link⁵, Steven M. Kornblau¹, Rashmi Kanagal-Shamanna⁶, Carlos E. Bueso-Ramos⁶, and Sean M. Post^{1**}

Affiliations:

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

²The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA

³School of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁴Baylor College of Medicine, Houston, TX, USA

⁵Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁶Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

*These authors contributed equally

**To whom correspondence should be addressed

Corresponding Author: Sean M. Post, Ph.D.

Email: spost@mdanderson.org

Department of Leukemia, The University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Houston, TX 77030, USA

Running title: hnRNP K overexpression in AML

Keywords: hnRNP K, RNA-binding protein, splicing, RUNX1, leukemia, mouse model

Highlights

- hnRNP K, an RNA binding protein, is overexpressed in AML and correlates with poor clinical outcomes
- hnRNP K overexpression in murine HSPCs drives fatal myeloproliferative phenotypes in mice
- hnRNP K's oncogenicity can be attributed, at least in part, to its ability to bind and influence the splicing of the *RUNX1* transcript

Summary

Acute myeloid leukemia (AML) is driven by numerous molecular events that contribute to disease progression. Herein, we identified hnRNP K overexpression as a recurrent abnormality in AML that is associated with inferior patient outcomes. In murine hematopoietic stem and progenitor cells, hnRNP K overexpression altered self-renewal and differentiation potential. Furthermore, murine transplantation models revealed that hnRNP K overexpression resulted in fatal myeloproliferative phenotypes. Using unbiased approaches, we discovered a direct relationship between hnRNP K and *RUNX1*—a master transcriptional regulator of hematopoiesis often dysregulated in leukemia. Molecular analyses revealed hnRNP K-dependent alternative splicing of *RUNX1*, resulting in the generation of a functionally distinct isoform. Taken together, we have established hnRNP K as an oncogene in myeloid leukemia that binds *RUNX1* RNA, altering its splicing and subsequent transcriptional activity. These findings shed new light on a mechanism of myeloid leukemogenesis, paving the way for new drug discovery efforts.

Introduction

Acute myeloid leukemia (AML) is an often devastating hematologic malignancy wherein normal hematopoiesis is superseded by rapid proliferation of incompletely differentiated myeloid cells. Taken as a whole, younger patients (<60 years) with AML have a 5-year overall survival of approximately 40%, while older patients tend to have much worse outcomes, with 5-year OS verging on 10% (Dohner et al., 2015; Juliusson et al., 2009; Slovak et al., 2000). Identification of recurrent genomic events in AML (e.g.; mutations in *FLT3* or *IDH1/2*) has led to development of targeted therapeutic agents that improve patient outcomes and quality of life; however, many patients lack these genomic alterations, rendering them ineligible for such treatments. Furthermore, despite prolonging life, patients treated with these agents are often still at risk for relapse (DiNardo et al., 2018; Perl et al., 2019; Stein et al., 2019; Stone et al., 2017), highlighting the need to understand the molecular underpinnings of AML such that alternative, effective therapeutic options can be developed.

Myeloid malignancies, including AML and its frequently associated precursor condition myelodysplastic syndrome (MDS), often have alterations in RNA-binding proteins (RBPs). Splicing factors such as SRSF2, SF3B1, and U2AF1 are widely known RBPs in this context, and are often mutated (Graubert et al., 2011; Papaemmanuil et al., 2011; Yoshida et al., 2011). Importantly, other RBPs such as MUSASHI2, METTL3 are also aberrantly expressed, though infrequently mutated, in hematologic malignancies, and have been identified as critical to the pathogenesis of AML (Kharas et al., 2010b; Saha et al., 2019; Vu et al., 2017; Wang et al., 2019). Drugs targeting splicing or other RNA-binding properties of these proteins have been developed with therapeutic intent (Minuesa et al., 2019; Seiler et al., 2018). However, the roles of other RBPs in myeloid malignancies, including AML, have not been extensively deciphered.

An RBP of accumulating interest in hematologic and solid malignancies is heterogeneous nuclear ribonucleoprotein K (hnRNP K). Overexpression of hnRNP K has been

associated with adverse pathology in a handful of small clinical studies evaluating solid tumors (Barboro et al., 2009; Carpenter et al., 2006; Chen et al., 2010; Wen et al., 2010; Zhou et al., 2010). Further, elevated hnRNP K expression is not uncommon in B-cell lymphoma and has been defined as an oncogene in this setting (Gallardo et al., 2019). These findings led to consideration that hnRNP K aberrancies may contribute to a broader array of hematologic malignancies. Because the expression and role of hnRNP K in AML is less clear, we sought to evaluate hnRNP K in this context.

Aberrations of RBPs often impact the expression of genes or proteins implicated in hematologic malignancies. For instance, RUNX1 is a crucial hematopoietic transcription factor with several isoforms that emerge due to alternative promoter usage and alternative splicing (Ghozi et al., 1996; Komeno et al., 2014; Miyoshi et al., 1995; Tanaka et al., 1995). *RUNX1* is a common target of translocations or mutations in leukemias, including AML (De Braekeleer et al., 2011; Osato, 2004; Osato et al., 1999). Interestingly, expression of different *RUNX1* isoforms arising via alternative splicing, specifically around exon 6, also alter hematopoiesis (Ghanem et al., 2018; Komeno et al., 2014; Sun et al., 2020).

In this study, we address the hypothesis that hnRNP K is overexpressed in AML, impacts clinic outcomes, and that this overexpression contributes to myeloid aberrations in a murine model. We find that hnRNP K overexpression leads to extramedullary hematopoiesis, gross hematopoietic abnormalities, and premature death in mice. Mechanistically, we identified that hnRNP K alters *RUNX1* splicing via its RNA-binding properties. hnRNP K interacts with *RUNX1* RNA in a sequence-specific manner, in humans and mice, and causes exclusion of *RUNX1* exon 6 (*RUNX1*ΔEx6), ultimately leading to expression of a more stable RUNX1 isoform with altered transcriptional activity. Further, expression of RUNX1ΔEx6 recapitulates an *in vitro* phenotype associated with hnRNP K overexpression, supporting the notion that hnRNP K mediates its hematopoietic alterations, at least in part, via altered *RUNX1* splicing. Finally, we

identify that the RNA-binding KH3 domain of hnRNP K is a critical mediator of this *RUNX1* splicing event.

Taken together, these studies identify hnRNP K as a potential driver alteration in AML, nominating this protein as a putative drug target. In addition, hnRNP K-mediated altered splicing of *RUNX1* provides an alternate mechanism whereby *RUNX1* is altered in AML in the absence of mutations or translocations. Finally, the methods used in this manuscript and the identification of specific domains of hnRNP K implicated in this splicing alteration provide a valuable set of tools to develop drugs that specifically disrupt hnRNP K-RNA interactions.

Methods

Reverse phase protein array (RPPA) data: Data is publicly available at www.leukemiaatlas.org (Hu et al., 2019). hnRNP K protein expression was compared to the median of healthy donor CD34+ bone marrow specimens.

Plasmids: For generation of stable cell lines, lentiviral plasmids containing full-length hnRNP K, hnRNP K domain deletions, full-length *RUNX1*, or *RUNX1*ΔEx6 cDNA were cloned into the XhoI/NotI sites in the all-in-one tetracycline inducible lentiviral vector TRE3G-ORF-P2A-eGFP-PGK-Tet3G-bsd (TLO2026, transOMIC Technologies, Huntsville, AL). For retroviral plasmids used in fetal liver cells, the MSCV-AML1/ETO-IRES-GFP plasmid was obtained from Addgene (Addgene plasmid #60832; <http://n2t.net/addgene:60832>; RRID:Addgene_60832 (Zuber et al., 2009)) and *AML1/ETO* cDNA replaced with *HNRNPK*, *HNRNPK*ΔKH3, *RUNX1(b)*, or *RUNX1*ΔEx6 amplified from cDNA obtained from 293T cells and the pINDUCER-21-*RUNX1* plasmid (Addgene plasmid #97043; <http://n2t.net/addgene:97043>; RRID:Addgene_97043 (Sugimura et al., 2017)), respectively. Cloning was done in XhoI/EcoRI sites in the MSCV-IRES-GFP plasmid. For generation of stably knocked down cell lines, tetracycline-inducible human

HNRNPK PGK-TurboRFP shRNAs were purchased from Dharmacon (clone ID: V3IHSPGR_10844995 mature antisense TCGACGAGGGCTCATATCA, targeting exon 10), and two targeting the 3' UTR, referred to as shHNRNPK ex16-1 (clone ID: V3IHSPGR_5114248, mature antisense AAGACACTAGAGCAAATTG) and shHNRNPK ex16-2 (clone ID: V3IHSPGR_9103684, mature antisense ATAAAATCCACTCACTCTG), and control PGK-TurboRFP (VSC11656, mature antisense TGGTTTACATGTTGTGTGA; Lafayette, CO).

For transient transfections, hnRNP K domain deletions (amplified with nested PCR (Ho et al., 1989)), *RUNX1(b)*, or *RUNX1ΔEx6* were ligated into XhoI/EcoRI restriction sites in the c-Flag pcDNA3vector (Addgene plasmid #20011; <http://n2t.net/addgene:20011>; RRID:Addgene_20011) (Sanjabi et al., 2005). Reporter assays to assess RUNX1 transcriptional activity were done using the pMCSF-R-luc plasmid (Addgene plasmid #12420; <http://n2t.net/addgene:12420>; RRID:Addgene_12420) (Zhang et al., 1994). The pCMV β-galactosidase plasmid was a gift from Dr. Vrushank Davé (University of South Florida).

Stable cell line generation: Cell lines were spun for 90 minutes at 600 x g with filtered viral supernatant from 293T cells transfected with indicated plasmids (see above), and pCMV-VSV-G/pCMV-dR8.2 for human cell lines (Addgene plasmid #8454; <http://n2t.net/addgene:8454>; RRID:Addgene_8454 and Addgene plasmid #8455; <http://n2t.net/addgene:8455>; RRID:Addgene_8455, respectively (Stewart et al., 2003)) or pCL-ECO for fetal liver cells (Addgene plasmid #12371; <http://n2t.net/addgene:12371>; RRID:Addgene_12371 (Naviaux et al., 1996)). Human cells were selected in antibiotic (puromycin or blasticidin, Fisher Scientific, Waltham, MA) and appropriate fluorescence >90% required prior to downstream assays. Cells were maintained in strict tetracycline-free conditions until induction with 0.2 μg/mL doxycycline (Sigma-Aldrich, St. Louis, MO) for shRNA and 0.4 μg/mL doxycycline for overexpression. HSPCs were sorted for GFP positivity 72 hours after infection.

HSPC isolation, transduction, and transplantation: All mouse studies were performed with approval from the Institutional Animal Care and Use Committee at MD Anderson under protocol 0000787-RN01/2. Pregnant wildtype CD45.2⁺ C57Bl/6 females were euthanized via CO₂ exposure at day 13.5 of gestation, fetal livers dissected, and disrupted on a 70 µm filter into single-cell suspension. Cells were briefly subjected to red blood cell lysis (BD Pharm Lyse, BD Biosciences, San Jose, CA) and resuspended in medium containing 37% DMEM (Corning Inc, Corning, NY), 37% Iscove's modified Dulbecco's Medium (Corning Inc, Corning, NY), 20% fetal bovine serum, 2% L-glutamine (200mM; Corning Inc, Corning, NY), 100 U/mL penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO), 5x10⁻⁵ M 2-mercaptoethanol (Sigma-Aldrich, St. Louis, MO), recombinant murine IL-3 (0.2 ng/mL), IL-6 (2 ng/mL), and SCF (20 ng/mL; Stem Cell Technologies, Vancouver, BC) at high density overnight at 37°C prior to retroviral transduction (Schmitt et al., 2002; Zuber et al., 2009). For transplantation assays, NOD-scid-IL2R-gamma (NSG) mice were irradiated with 2.5 Gy prior to injection of 50,000 sorted cells into the retro-orbital sinus.

Immunoblotting: Cells were homogenized in NP40 lysis buffer and standard immunoblotting procedures performed as previously described (Gallardo et al., 2019) using antibodies against hnRNP K (3C2), RUNX1 (EPR3099, both from Abcam, Cambridge, MA), β-actin (AC-15, Santa Cruz Biotechnology, Dallas, TX), Flag (F1804, Sigma Aldrich), HSP90 (ADI-SPA-836-D, Enzo Life Sciences)

Colony formation assay: GFP-sorted HSPCs were cultured in Methocult (M3434, StemCell Technologies, Vancouver, BC). Colonies were counted after 7 days then gently disrupted in PBS and cells counted subjected to cytospin or flow cytometry.

Flow cytometry: Cells were pre-treated with murine Fc block (TruStain FcX, BioLegend, San Diego, CA,) at room temperature for 15 minutes then incubated with antibodies Gr1 [RB6-8C5],

CD11b [M1/70;], CD117 [2B8], CD45 [30F11] (all from BD Biosciences, East Rutherford, NJ), and Sca-1 [D7; eBioscience, San Diego, CA,]. Flow cytometry was performed on a Gallios flow cytometer (Beckman Coulter, Brea, CA,). Data was analyzed using FlowJo (Beckton Dickinson, Franklin Lakes, NJ).

Tissue harvest: Spleen, liver, and sternum were collected and immediately fixed in 10% neutral-buffered formalin. Paraffin-embedded blocks were sectioned and stained with standard hematoxylin/eosin. Cells were also collected from femurs and a portion of the spleen in a single cell suspension, subjected to RBC lysis, and processed for western blotting or qRT-PCR as described herein.

Immunohistochemistry: Formalin-fixed paraffin-embedded tissues were deparaffinized in xylene and rehydrated in an alcohol gradient. Following antigen retrieval with citrate (pH 6.0), slides were incubated with 3% hydrogen peroxide/methanol prior to incubation with primary antibody at 4°C overnight. Primary antibodies: hnRNP K [3C2], CD3 [SP162], MPO [ab9535], CD14 [4B4F12] (Abcam, Cambridge, MA), CD34 [MEC14.7], CD117 [2B8] (ThermoFisher Scientific, Waltham, MA). Antibody-protein interactions were visualized with Vectastain Elite ABC and DAB peroxidase substrate kits (Vector Laboratories, Burlingame, CA) and counterstained with nuclear fast red.

Peripheral blood analysis: Complete blood counts were performed with an ABX Pentra analyzer (Horiba, Kyoto, Japan). Peripheral blood smears were stained with Wright-Giemsa.

RNA-Sequencing: RNA was extracted and purified from GFP+ sorted HSPCs using Zymo Quick-RNA columns (Zymo Research, Irvine, CA). Barcoded, Illumina-stranded total RNA libraries were prepared using the TruSeq Stranded Total RNA Sample Preparation Kit (Illumina, San Diego, CA). Briefly, 250ng of DNase I-treated total RNA was depleted of cytoplasmic and

mitochondrial ribosomal RNA (rRNA) using Ribo-Zero Gold (Illumina, San Diego, CA). After purification, RNA was fragmented using divalent cations and double stranded cDNA was synthesized using random primers. The ends of the resulting double stranded cDNA fragments were repaired, 5'-phosphorylated, 3'-A tailed and Illumina-specific indexed adapters were ligated. The products were purified and enriched by 12 cycles of PCR to create the final cDNA library. The libraries were quantified by qPCR and assessed for size distribution using the 4200 TapeStation High Sensitivity D1000 ScreenTape (Agilent Technologies, Santa Clara, CA) then multiplexed 3 libraries per lane and sequenced on the Illumina HiSeq4000 sequencer (Illumina, San Diego, CA) using the 75 bp paired end format.

RNA-Seq analysis: Fastq files were pseudoaligned using Kallisto v0.44.0 (Bray et al., 2016) with 30 bootstrap samples to a transcriptome index based on the *Mus musculus* GRCm38 release (Ensembl). The resulting abundance data was further analyzed with Sleuth v0.30.0 (Pimentel et al., 2017) using models with covariates for both batch and condition. Gene-level 80 abundance estimates were calculated as the sum of transcripts per million (TPM) estimates of all transcripts mapped to a given gene. Wald tests were performed at a gene level for the “condition” covariate with a significance threshold of FDR <10%.

fRIP analysis: Previously published data deposited to the Gene Expression Omnibus (GSE126479) was cross-referenced with known tumor suppressors and oncogenes.

Identification of putative hnRNP K binding sites: As described previously (Gallardo et al., 2019), a computer-based algorithm was used that scan transcripts of interest for two or more (U/C)CCC motifs within 19 nucleotides.

Fluorescence anisotropy (FA): Recombinant hnRNP K protein, produced in E.coli as described previously (Gallardo et al., 2019), was serially diluted in PBS (0.1 nM to 10 μ M) and incubated

with 6-FAM labelled RNA oligonucleotides. FA values were measured with excitation wavelength 485 nm and emission wavelength 528 nm on a Synergy Neo multi-mode plate reader (BioTek, Winooski, VT). Data was fit to the following equation: $FA = FA_i + B_{max} * [oligo] / (K_d + [oligo])$ where initial FA is represented by FA_i and the overall change in FA is represented by B_{max} . Oligos: hRUNX1 5'UTR: CGCCCCCCCCACCCCCCGCAGUAAUAAAGGCCCCUGA, hRUNX1 5'UTR(mut) CGCGCGCGCGCACGCGCCGCAGUAAUAAAGGCGCCUGA, hRUNX1 int5-6 UCUCUUCCCUCCCUCCUUCCCUCCCCCAU, hRUNX1 int5-6(mut) UCUGUUCGCUCGCUCGUUCGCUCGCGCCAU, mRunx1 int5-6 UCCUCCUCCCUUCCCCUCCCGGUCCCUA, mRunx1 int5-6(mut) UCCUCCUCGCUUCGCCUCGCGGUCCCUA.

Thermal shift assays: Recombinant hnRNP K protein (Gallardo et al., 2019) was incubated with SYPRO orange dye in the presence of DNA oligos [the DNA equivalent to RNA oligos used in FA assays]. Samples were heated from 25°C to 99°C in PBS buffer and fluorescence measured at each temperature increment using a StepOne Plus Real Time PCR System (Applied Biosystem, Foster City, CA). Negative controls with no protein were run on each plate. The first derivative of fluorescence was calculated at each temperature and the temperature corresponding to the minima was designated as the melting temperature of the sample.

RT-PCR for RUNX1 isoforms: Equal amount of RNA per sample was converted to cDNA with iScript (BioRad, Hercules, CA). Standard PCR conditions were used to amplify cDNA using a BioRad Thermocycler at 95°C x 3 minutes, followed by 35 cycles of 95°C for 1 minute, 60°C for 1 minute, and 72°C for 3 minutes, and finally 72°C for 5 minutes. After amplification, equal amounts of PCR products were run on a 2% agarose gel with ethidium bromide and visualized using a Syngene G:Box EF2 gel doc system with GENESys image capture software. Primers

246 (5' to 3'): hRUNX1 (exon 5) forward GAAGTGGAGAGGGAAAAGCTTCA, hRUNX1 (exon 7)
 247 reverse GCACGTCCAGGTGAAATGCG, hPPIA forward CCCACCGTGTTCTTCGACATT,
 248 hPPIA reverse GGACCCGTATGCTTTAGGATGA, mRunx1 (exon 5) forward
 249 CACTCTGACCATCACCGTCTT, mRunx1 (exon 7) reverse GGATCCCAGGTACTGGTAGGA,
 250 mPPIA forward GAGCTGTTTGCAGACAAAGTTC, mPPIA reverse
 251 CCCTGGCACATGAATCCTGG.

252 *Sanger Sequencing:* DNA was purified from agarose gels using a gel purification kit (Invitrogen,
 253 Carlsbad, CA). Sequencing was performed on an ABI 3730XL sequencer using BigDye
 254 terminator cycle sequencing chemistry with the forward primer used in the RT-PCR reaction.
 255 For validation, another sequencing run was performed with the reverse primer used in the RT-
 256 PCR reaction. Data was provided as text files and chromatograms.

257 *Clinical RUNX1 isoform expression analysis:* RNA-seq expression data for the full-length
 258 (ENST00000344691.8) and Δ Ex6 (ENST00000399240.5) *RUNX1* isoforms and corresponding
 259 clinical data for 350 patients with AML from the BEAT AML 1.0 cohort was downloaded through
 260 the Vizome data portal (<https://vizome.org/>) February 2020 (Tyner et al., 2018).

261 *Protein stability assays:* 293T cells stably transduced with tetracycline-inducible constructs to
 262 overexpress *RUNX1*, either full-length or lacking exon 6. 400 ng/mL doxycycline was added to
 263 cells prior to the addition of cycloheximide (10 μ M, Sigma-Aldrich, St. Louis, MO) with or without
 264 MG-132 (10 μ M, SelleckChem, Houston, TX) for 1-8 hours. Cells were collected and lysed in
 265 NP40 lysis buffer with protease and phosphatase inhibitors prior to western blot.

266 *Transfections:* 293T cells were plated at identical confluencies and transfected using equal
 267 amounts of DNA with JetPrime reagents as per manufacturer's instructions (Polyplus
 268 Transfection, NY). All transfections were for 48 hours unless otherwise noted.

Reporter assays: The M-CSF promoter reporter (pMCSF-R-luc Addgene plasmid # 12420; <http://n2t.net/addgene:12420>; RRID: Addgene_12420)(Zhang et al., 1994) was used to assess RUNX1 transcriptional activity. 293T cells were transiently transfected with luciferase-based reporter plasmids and expression plasmids using jetPRIME (Polyplus, New York, NY). Total DNA quantity was constant across all wells. 48 hours post-transfection, luciferase assay reagent was mixed in a 1:1 ratio with cell lysate (Luciferase Assay System kit, Promega, Madison, WI). Luciferase activity was measured with Synergy H4 Hybrid Reader (BioTek, Winooski, VT). Transfection efficiency for each well was normalized using 62.5ng of a pCMV β -galactosidase plasmid, which was co-expressed in each experiment.

Results

hnRNP K is overexpressed in AML patient samples and correlates with poor clinical outcomes

We first assessed hnRNP K protein expression in AML using a publicly available reverse phase protein array (RPPA) dataset (Hu et al., 2019). While hnRNP K expression varied, AML cases had significantly higher median hnRNP K expression compared to healthy human bone marrow ($p=0.0056$, Fig 1A). As expected, a small percentage of cases had decreased hnRNP K expression, consistent with previous descriptions of *HNRNPK* haploinsufficiency corresponding with del(9q) (Gallardo et al., 2015; Kronke et al., 2013; Peniket et al., 2005). Increased hnRNP K expression was further associated with a statistically significant decrease in overall survival (OS; 24.3 months versus 48.7 months; HR 1.9; 95% CI 1.3-2.7; Figure 1B). Thus, stratification of patients based solely on hnRNP K overexpression was sufficient to elucidate a subset of patients with an inferior clinical outcome, suggesting that increased amounts of hnRNP K may be involved in the pathology of AML.

We considered the possibility that increased levels of hnRNP K could be a consequence of mutation. In line with the findings of others, a mere 2.9% of AML cases at our institution were

found to have an *HNRNPK* mutation (Supplemental Figure 1) (Cancer Genome Atlas Research et al., 2013; Papaemmanuil et al., 2016; Tyner et al., 2018). Given the discordance between this small mutational occurrence and the relatively large proportion of AML cases with elevated hnRNP K protein levels, we therefore posit that increased hnRNP K is of the wildtype form.

hnRNP K overexpression impacts the differentiation potential of HSPCs

To evaluate a possible role of hnRNP K overexpression in myeloid disease, we overexpressed wildtype hnRNP K in murine hematopoietic stem and progenitor cells (HSPCs). Robust overexpression of hnRNP K was observed at the protein level (Figure 2A). *In vitro*, hnRNP K-overexpressing cells exhibited a significant increase in colony formation ($p=0.008$, Figures 2B-C), suggesting that elevated hnRNP K may influence self-renewal capacity of HSPCs. Flow cytometry revealed that hnRNP K-overexpressing colonies were composed of fewer Gr1⁺CD11b⁺ mature myeloid cells compared to controls (Figures 2D-E). However, immature c-kit⁺Sca-1⁺ cells were more prominent in hnRNP K-overexpressing colonies compared to controls (Figures 2D-E). These data suggested that hnRNP K overexpression hinders HSPC differentiation into mature myeloid cells and may be involved in myeloid leukemogenesis.

Overexpression of wildtype hnRNP K is sufficient to drive myeloid disease in mice

Because hnRNP K overexpression was observed in AML and correlated with poor clinical outcomes, we sought to directly evaluate if overexpression of wildtype hnRNP K was sufficient to drive myeloid disease. To this end, we injected murine HSPCs overexpressing wildtype hnRNP K or an empty vector control into sub-lethally irradiated NSG mice. Recipients of hnRNP K-overexpressing HSPCs had markedly shortened survival compared to recipients of control HSPCs (median survival 8.1 weeks versus median not reached (HR 3.0, 95% CI 1.2 – 7.3, $p=0.02$; Figure 3A), despite similar engraftment between groups (Figure 3B).

Analysis of peripheral blood revealed that recipients of hnRNP K-overexpressing HSPCs had modest leukocytosis (Supplemental Figure 2A), while hemoglobin and platelet counts were not significantly changed between groups (Supplemental Figures 2B-C). Therefore, hnRNP K-overexpression appears to selectively affect the leukocyte compartment in our murine model. Indeed, mature neutrophils were less abundant in peripheral blood of mice transplanted with hnRNP K-overexpressing HSPCs (Supplemental Figure 2D). While the percentage of circulating monocytes or eosinophils did not differ between groups (Supplemental Figures 2E-F), hnRNP K-overexpression caused a slight increase in lymphocytes (Supplemental Figure 2G).

Given the peripheral blood abnormalities, we next evaluated bone marrow. Recipients of hnRNP K-overexpressing HSPCs had more cellular bone marrow than control recipients (Figure 3C). In addition, myeloid cells were overrepresented in bone marrow containing hnRNP K-overexpressing cells, and mild eosinophilia was observed (Figure 3C).

Given these abnormalities, we examined other hematopoietic organs. Splenomegaly was observed in recipients of hnRNP K-overexpressing HSPCs (Figure 3D-E) and histologic evaluation revealed starkly disrupted splenic architecture in recipients of hnRNP K-overexpressing HSPCs that corresponded with increased hnRNP K expression (Figure 3F). Immunohistochemistry on spleens from recipients of hnRNP K-overexpressing HSPCs showed CD34 and CD117 positive cells, indicating the presence of immature hematopoietic cells in this organ (Supplemental Figure 3A), which is in line with our observations from the colony formation assays.

Recipients of hnRNP K-overexpressing HSPCs also harbored infiltrations of leukocytes into the hepatic parenchyma that were not present in mice transplanted with empty vector-containing HSPCs (Supplemental Figure 3B). These hepatic infiltrates observed in recipients of hnRNP K-overexpressing HSPCs were largely negative for CD3, but positive for CD117, CD14, and myeloperoxidase (MPO; Supplemental Figure 3C), indicating that immature hematopoietic cells and cells of myeloid origin were present in this organ. Notably, lack of CD3 expression largely

ruled out a graft versus host effect. Taken together, these data indicate that hnRNP K overexpression in hematopoietic stem and progenitor cells is sufficient to drive fatal myeloid disease in mice.

hnRNP K binds to and influences the alternative splicing of the *RUNX1* transcript

Next, we wanted to understand a mechanistic basis for hnRNP K's influence on myeloid development. To this end, we performed RNA-Seq on hnRNP K-overexpressing HSPCs. In addition to differences in gene expression (Supplemental Figure 4A), we observed statistically significant changes in numerous RNA splicing events (Figure 4A). Given the RNA-binding properties of hnRNP K coupled with the increasing appreciation for altered splicing events in hematologic malignancies, we focused on differentially spliced genes. When we specifically evaluated hematopoietic genes that were differentially spliced in the context of hnRNP K overexpression, we identified *Runx1* as one of the most significantly differentially spliced genes (Figure 4B). This was a particularly intriguing finding, as *RUNX1* was also among the transcripts most significantly associated with hnRNP K in an hnRNP K RNA-immunoprecipitation dataset in a human AML cell line generated from our lab (GSE 126479; Figure 4C (Gallardo et al., 2019)). These data, as well as the well-described role of *RUNX1* as a critical mediator in many leukemias, led us to focus on studying this target.

While hnRNP K has been associated with *Runx1* splicing (Cao et al., 2012), this has not been described in the context of hnRNP K overexpression, nor has a direct interaction between hnRNP K and *Runx1* RNA been characterized. Therefore, we used our previously developed computer algorithm to identify putative hnRNP K binding sites within human *RUNX1* or mouse *Runx1* transcripts (Gallardo et al., 2019). Two putative hnRNP K binding sites were identified in human *RUNX1*— one near the 3' splice site of the intron 5-6 junction and one in the 5' untranslated region (UTR) of *RUNX1b/c* (Figure 4D). Notably, only the intron 5-6 site was

conserved in murine *Runx1*, which is consistent with a previous report of a similar site in the rat homolog (Cao et al., 2012).

To assess whether hnRNP K directly bound these sites in *RUNX1* RNA, we performed fluorescence anisotropy assays. Indeed, purified hnRNP K protein stringently bound the intron 5-6 site in both human and mouse *RUNX1* (Figures 4E-F). hnRNP K also bound tightly to the predicted site in the 5' UTR of human *RUNX1* RNA (Supplemental Figure 4B). In all cases, the hnRNP K-*RUNX1* interaction was abrogated when the hnRNP K consensus binding site was mutated (Figures 4E-F, Supplementary Figure 4B), indicating that hnRNP K binds *RUNX1* directly and in a sequence-specific manner. These findings were confirmed in thermal shift assays, where hnRNP K was stabilized (i.e. had an increased melting temperature) in the presence of the conserved nucleic acid sequence corresponding to intron 5-6 in both human and murine *RUNX1* (Supplemental Figure 4C). As with the fluorescence anisotropy assays, mutations in the hnRNP K binding site diminished the ability of hnRNP K to be stabilized by these oligonucleotides (Supplemental Figure 4C).

Given the similarity between the hnRNP K binding site in *RUNX1* intron 5-6 in mouse and human, as well as RNA-Seq data identifying (Figure 4) that the *Runx1* splicing alterations surrounded exon 6, we focused our efforts on this site. Indeed, PCR amplification spanning exons 5 through 7 of *Runx1* in HSPCs validated the observations from RNA-Seq that an isoform of *Runx1* lacking exon 6 was enriched in hnRNP K-overexpressing HSPCs (Figure 5A). Sanger sequencing of a similar *RUNX1* PCR amplicon of exons 5-7 in human 293T cells further confirmed that the two PCR products amplified from this PCR contained exons 5-7 (referred to as FL *RUNX1*; 352 base pairs) or completely lacked exon 6 (referred to as *RUNX1*ΔEx6; 192 base pairs; Figure 5B). These results indicate that both *RUNX1* FL and *RUNX1*ΔEx6 isoforms are present in both human and mouse.

The *RUNX1*Δ*Ex6* splice isoform is present in AML patient samples

While these isoforms of *RUNX1* were present in human and mouse, we wanted to examine whether these were also present in human AML samples. Indeed, *RUNX1*Δ*Ex6* was prominent in bone marrow and peripheral blood of patients with AML (Figure 5C). Analysis of publicly available data also corroborated the presence of this *RUNX1*Δ*Ex6* in AML (Supplementary Figure 5A). This suggests that alterations in *RUNX1* splicing involving exon 6 inclusion are clinically evident and may be relevant.

hnRNP K expression levels regulate the generation of the *RUNX1*Δ*Ex6* splice isoform

To explicitly understand how hnRNP K levels mediate this splicing event, we developed several inducible hnRNP K-overexpressing human leukemia cell lines (Supplemental Figure 5B). In each case, cells that overexpressed hnRNP K had a relative enrichment of *RUNX1*Δ*Ex6* at the expense of *RUNX1* *FL* compared to cells expressing an empty vector control (Figure 5D). Strikingly, knockdown of hnRNP K induced the opposite effect, as cells transduced with sh*HNRNPK* had increased *RUNX1* *FL* at the expense of *RUNX1*Δ*Ex6* (Figure 5E and Supplementary Figure 5C). Importantly, re-introduction of hnRNP K into the sh*HNRNPK*-knockdown cells rescued the relative proportion of *RUNX1* *FL* to *RUNX1*Δ*Ex6* to near that of controls (Figure 5F and Supplementary Figure 5D). This indicates that inclusion or exclusion of *RUNX1* exon 6 is dependent on hnRNP K levels. Importantly, this observation extended to the protein expression of *RUNX1* as well, where the shorter isoform of *RUNX1* was detectable at higher levels in the presence of hnRNP K overexpression (Supplemental Figure 5E). In contrast, knockdown of hnRNP K resulted in a reduction in the expression of this shorter *RUNX1* isoform (Supplemental Figure 5F).

The *RUNX1*Δ*Ex6* splice isoform has differential protein stability and function

Since hnRNP K overexpression leads to relative enrichment of *RUNX1ΔEx6*, we next sought to evaluate any functional consequences of lacking this exon. Cycloheximide chase assays, in cells with stable inducible expression of RUNX1 FL or RUNX1ΔEx6, demonstrated that RUNX1ΔEx6 was substantially more stable than RUNX1 FL, in line with previous observations (Figure 6A) (Komeno et al., 2014; Sun et al., 2020). This effect was almost completely abrogated by addition of MG132 (Figure 6B), indicating that exon 6 is a critical mediator of RUNX1 protein stability. This is consistent with reports that have identified ubiquitination sites in exon 6 of the RUNX1 protein (Biggs et al., 2006).

As RUNX1 is a well-defined transcription factor, we then queried whether lack of exon 6 would affect the transcriptional capabilities of this protein. Indeed, luciferase assays indicated that RUNX1 FL and RUNX1ΔEx6 had differential abilities to transactivate a promoter-reporter derived from the CSF1R promoter, which is known to have RUNX1 binding sites (Figure 6C). Together, our data demonstrate that RUNX1 FL and RUNX1ΔEx6 are phenotypically and functionally distinct isoforms.

To understand whether this isoform of RUNX1 may be responsible, in part, for mediating the hnRNP K-overexpression phenotype, we repeated colony formation assays using HSPCs. HSPCs overexpressing RUNX1ΔEx6 formed significantly more colonies *in vitro* than HSPCs overexpressing RUNX1 FL or an empty vector (Figure 6D). This increase in colony formation was similar to that observed with overexpression of hnRNP K (Figure 2B-C), suggesting that increased expression of RUNX1ΔEx6 may be partly responsible for this hnRNP K-mediated effect.

The KH3 RNA-binding domain of hnRNP K is required for the generation of the *RUNX1ΔEx6* splice isoform

Given the striking splicing differences observed with hnRNP K overexpression in both human and mouse, we next set out to determine which domain of the hnRNP K protein was responsible for mediating this splicing event as this could expedite future drug discovery efforts. When hnRNP K was overexpressed, the relative proportion of *RUNX1 FL* to *RUNX1ΔEx6* was decreased, as we had observed in earlier studies (Figure 6E and Supplemental Figure 6B). However, when hnRNP K lacking either the KNS or KH3 domain was overexpressed, this effect was largely mitigated, and the *RUNX1* splicing pattern resembled control cells (Figure 6E and Supplemental Figure 6). This suggests that isolated domains of hnRNP K (KH3 and possibly KNS) are responsible for the splicing surrounding *RUNX1* exon 6. Given that the splicing process occurs in the nucleus and requires direct RNA-binding activity, it is therefore understandable why either the RNA-binding KH3 domain or the nuclear localization KNS domain would be critical.

Since the KH3 domain of hnRNP K appeared to be largely responsible for the expression of *RUNX1ΔEx6*, we overexpressed the isoform of hnRNP K lacking KH3 in HSPCs and performed colony formation assays. Strikingly, the absence of KH3 completely reversed the increase in colony formation associated with overexpression of full-length hnRNP K (Figure 6F). This demonstrates that the KH3 domain is critical not only for splicing surrounding exon 6 of *RUNX1*, but also that the KH3 domain is required for hnRNP K to exert its pro-growth activity in HSPCs. Taken together, these data demonstrate that the RNA-binding protein hnRNP K is highly expressed in AML. Overexpression of wildtype, unmutated hnRNP K increases colony formation potential of HSPCs, while inhibiting terminal differentiation. These findings are echoed *in vivo*, where increased hnRNP K expression leads to a fatal myeloid disease. Mechanistically, hnRNP K directly binds *RUNX1* RNA in mouse and in human, and its overexpression results in an enrichment of the phenotypically and functionally distinct isoform of *RUNX1* lacking exon 6 (*RUNX1ΔEx6*). Going forward, development of drugs to disrupt hnRNP

K's interaction with RNA, perhaps by specifically targeting the KH3 domain of hnRNP K, may have therapeutic potential in hnRNP K-overexpressing malignancies, including AML.

Discussion

RNA-binding proteins (RBPs) are increasingly being considered as essential molecules in regulating normal and malignant hematopoiesis. Spatio-temporal regulation of the targets of RBPs allows for the development and function of different hematological lineages (Kharas et al., 2010a; Wang et al., 2019). Consequently, aberrant function of RBPs, either due to mutations or altered expression, results in pathogenic states in the hematopoietic system (Barbieri et al., 2017; Gallardo et al., 2019; Kharas et al., 2010a; Vu et al., 2017). In this work, we describe overexpression of the RNA-binding protein, hnRNP K, in AML.

hnRNP K is frequently altered in malignancies and other disease states. Mutations in hnRNP K are relatively rare in hematological malignancies, as assessed by our patient cohort at MD Anderson Cancer Center (Supplemental Figure 1) and published work by other groups (Cancer Genome Atlas Research et al., 2013; Papaemmanuil et al., 2016; Tyner et al., 2018). Deletions of chromosome 9q, which encompass the *HNRNPK* locus at 9q21.32, are also rare events in AML (Gallardo et al., 2015; Kronke et al., 2013; Sweetser et al., 2005), but there has been sufficient evidence to establish the role of hnRNP K as a contextual haploinsufficient tumor suppressor. On the other hand, clinical and biological studies from our group and others have also identified that that *increased* hnRNP K expression may play a role in both hematologic malignancies and solid tumors (Barboro et al., 2009; Carpenter et al., 2006; Chen et al., 2010; Wen et al., 2010; Zhou et al., 2010). Indeed, increased expression of hnRNP K appears to be the more common occurrence in blood cancers (Figure 1A, (Gallardo et al., 2019)).

In the present work, using a previously published database, we observe that hnRNP K is overexpressed in patients with AML and correlates with poor clinical outcomes. Given the low prevalence of hnRNP K mutations in AML, we posit that it is the wildtype form of hnRNP K that

is overexpressed. Further, molecular mechanisms that underlie the overexpression of hnRNP K in AML remain an active area of investigation in our laboratory.

To evaluate the direct role of hnRNP K in driving myeloid phenotypes, we used a murine HSPC transplant model. Transplantation of hnRNP K-overexpressing HSPCs into mice results in a fatal myeloproliferative phenotype. The aberrant myelopoiesis observed in our mouse model is intriguing for several reasons. We recently described a mouse model wherein B-cell lymphomas develop secondary to hnRNP K overexpression in B-cells (Gallardo et al., 2019). In the current study, where hnRNP K was overexpressed in HSPCs, no lymphomas were observed. This suggests that hnRNP K overexpression earlier in hematopoiesis promotes a myeloid bias and/or inhibits lymphoid differentiation. Consistent with this, microarray data in human hematopoiesis has revealed *HNRNPK* transcript expression is higher in myeloid-biased compared to lymphoid-biased progenitor cells (Novershtern et al., 2011; Verhaak et al., 2009). In addition, we observed similar phenotypes including shortened survival and myeloid hyperplasia in mice that are haploinsufficient for *Hnrnpk* (Gallardo et al., 2019), suggesting that normal hematopoiesis, particularly of the myeloid lineage, requires exquisitely tight regulation of hnRNP K expression.

Mechanistic studies reveal that hnRNP K overexpression results in altered pre-mRNA splicing events. One of the top genes that was differentially spliced was *RUNX1*, and we decided to focus on altered splicing of the *RUNX1* transcript given its critical role in myeloid biology. Specifically, overexpression of hnRNP K resulted in the preferential splicing and generation of a *RUNX1* isoform lacking exon 6. Even a small increase in the levels of the *RUNX1ΔEx6* isoform is likely to be physiologically relevant, given the drastically increased stability of the corresponding protein. The *Runx1ΔEx6* isoform exhibits higher self-renewal capacity in colony formation assays, which is in agreement with the findings of Komeno et al and Sun et al (Komeno et al., 2014; Sun et al., 2020). In addition, others have demonstrated a

depletion in the cellular pool of HSCs *in vivo* in mice lacking the *RUNX1* Δ Ex6 isoform, indicating the importance of tight regulation of splicing in hematopoiesis (Ghanem et al., 2018; Komeno et al., 2014).

Functionally, we observed that the *RUNX1* Δ Ex6 isoform has different transcriptional activities compared to the full-length isoform. This may be attributed to the fact that the protein domain encoded by exon 6 is responsible for the interaction between *RUNX1* and the transcriptional co-repressor SIN3A (Zhao et al., 2008). The region encoded by exon 6 also contains arginine methylation sites, and these post-translational modifications have been implicated in regulation of transcriptional activity (Zhao et al., 2008). The exact mechanisms by which the *RUNX1* Δ Ex6 isoform is generated and the molecular processes that impart functional diversity to this alternatively spliced isoform remains an active area of investigation. However, given the robust presence of this isoform in AML patient samples, it is likely to have a role in AML biology.

Taken together, our data demonstrate the pathogenicity of overexpression of a wild type RBP, hnRNP K, in AML. While the altered splicing of the *RUNX1* transcript is observed upon hnRNP K overexpression, it is unlikely to be the sole mechanism driving the oncogenicity of hnRNP K. However, this paper provides evidence that aberrant expression of an RBP can disrupt splicing within the cell and has far reaching cellular implications, including but not limited to altered transcription factor activities.

Acknowledgements

We would like to thank Kendra Allton, Sabrina Stratton, and other members of Dr. Michelle Barton's laboratory for helpful conversations, and Taghi Manshouri for technical assistance and collaborative efforts.

Funding

This study has been supported by funding from a National Cancer Institute Cancer Center Support grant (CA016672) to core facilities at MD Anderson Cancer Center. MJLA is a recipient of the Dr. John J. Kopchick Fellowship. This research has been aided by a grant from the Jane Coffin Childs Memorial Fund for Medical Research (PM), and the American Society of Hematology (PM), a National Cancer Institute/National Institutes of Health Award (R01CA207204, SMP), Leukemia and Lymphoma Society (6577-19, SMP).

Disclosure of conflicts of interest

The authors declare no conflict of interests.

References

- Barbieri, I., Tzelepis, K., Pandolfini, L., Shi, J., Millan-Zambrano, G., Robson, S.C., Aspris, D., Migliori, V., Bannister, A.J., Han, N., *et al.* (2017). Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control. *Nature* 552, 126-131.
- Barboro, P., Repaci, E., Rubagotti, A., Salvi, S., Boccardo, S., Spina, B., Truini, M., Introini, C., Puppo, P., Ferrari, N., *et al.* (2009). Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. *British journal of cancer* 100, 1608-1616.
- Biggs, J.R., Peterson, L.F., Zhang, Y., Kraft, A.S., and Zhang, D.E. (2006). AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. *Molecular and cellular biology* 26, 7420-7429.
- Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-seq quantification. *Nat Biotechnol* 34, 525-527.
- Cancer Genome Atlas Research, N., Ley, T.J., Miller, C., Ding, L., Raphael, B.J., Mungall, A.J., Robertson, A., Hoadley, K., Triche, T.J., Jr., Laird, P.W., *et al.* (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med* 368, 2059-2074.
- Cao, W., Razanau, A., Feng, D., Lobo, V.G., and Xie, J. (2012). Control of alternative splicing by forskolin through hnRNP K during neuronal differentiation. *Nucleic acids research* 40, 8059-8071.
- Carpenter, B., McKay, M., Dundas, S.R., Lawrie, L.C., Telfer, C., and Murray, G.I. (2006). Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. *British journal of cancer* 95, 921-927.

578 Chen, L.C., Chung, I.C., Hsueh, C., Tsang, N.M., Chi, L.M., Liang, Y., Chen, C.C., Wang, L.J.,
579 and Chang, Y.S. (2010). The antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear
580 ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma
581 patients. *Cell Death Differ* 17, 1463-1473.

582 De Braekeleer, E., Douet-Guilbert, N., Morel, F., Le Bris, M.J., Ferec, C., and De Braekeleer, M.
583 (2011). RUNX1 translocations and fusion genes in malignant hemopathies. *Future Oncol* 7, 77-
584 91.

585 DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Swords, R.,
586 Collins, R.H., Mannis, G.N., Pollyea, D.A., *et al.* (2018). Durable Remissions with Ivosidenib in
587 IDH1-Mutated Relapsed or Refractory AML. *N Engl J Med* 378, 2386-2398.

588 Dohner, H., Weisdorf, D.J., and Bloomfield, C.D. (2015). Acute Myeloid Leukemia. *N Engl J*
589 *Med* 373, 1136-1152.

590 Gallardo, M., Lee, H.J., Zhang, X., Bueso-Ramos, C., Paeon, L.R., McArthur, M., Multani, A.,
591 Nazha, A., Manshouri, T., Parker-Thornburg, J., *et al.* (2015). hnRNP K Is a Haploinsufficient
592 Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic
593 Malignancies. *Cancer cell* 28, 486-499.

594 Gallardo, M., Malaney, P., Aitken, M.J.L., Zhang, X., Link, T.M., Shah, V., Alybayev, S., Wu,
595 M.H., Paeon, L.R., Ma, H., *et al.* (2019). Uncovering the role of hnRNP K, an RNA-binding
596 protein, in B-cell lymphomas. *J Natl Cancer Inst.*

597 Ghanem, L.R., Kromer, A., Silverman, I.M., Ji, X., Gazzara, M., Nguyen, N., Aguilar, G.,
598 Martinelli, M., Barash, Y., and Liehaber, S.A. (2018). Poly(C)-Binding Protein Pcbp2 Enables
599 Differentiation of Definitive Erythropoiesis by Directing Functional Splicing of the Runx1
600 Transcript. *Molecular and cellular biology* 38.

601 Ghozi, M.C., Bernstein, Y., Negreanu, V., Levanon, D., and Groner, Y. (1996). Expression of the
602 human acute myeloid leukemia gene AML1 is regulated by two promoter regions. *Proceedings*
603 *of the National Academy of Sciences of the United States of America* 93, 1935-1940.

604 Graubert, T.A., Shen, D., Ding, L., Okeyo-Owuor, T., Lunn, C.L., Shao, J., Krysiak, K., Harris,
605 C.C., Koboldt, D.C., Larson, D.E., *et al.* (2011). Recurrent mutations in the U2AF1 splicing
606 factor in myelodysplastic syndromes. *Nat Genet* 44, 53-57.

607 Ho, S.N., Hunt, H.D., Horton, R.M., Pullen, J.K., and Pease, L.R. (1989). Site-directed
608 mutagenesis by overlap extension using the polymerase chain reaction. *Gene* 77, 51-59.

609 Hu, C.W., Qiu, Y., Ligeralde, A., Raybon, A.Y., Yoo, S.Y., Coombes, K.R., Qutub, A.A., and
610 Kornblau, S.M. (2019). A quantitative analysis of heterogeneities and hallmarks in acute
611 myelogenous leukaemia. *Nat Biomed Eng* 3, 889-901.

612 Juliusson, G., Antunovic, P., Derolf, A., Lehmann, S., Mollgard, L., Stockelberg, D., Tidefelt, U.,
613 Wahlin, A., and Hoglund, M. (2009). Age and acute myeloid leukemia: real world data on
614 decision to treat and outcomes from the Swedish Acute Leukemia Registry. *Blood* 113, 4179-
615 4187.

616 Kharas, M.G., Lengner, C.J., Al-Shahrour, F., Bullinger, L., Ball, B., Zaidi, S., Morgan, K., Tam,
617 W., Paktinat, M., and Okabe, R. (2010a). Musashi-2 regulates normal hematopoiesis and
618 promotes aggressive myeloid leukemia. *Nature medicine* 16, 903-908.

619 Kharas, M.G., Lengner, C.J., Al-Shahrour, F., Bullinger, L., Ball, B., Zaidi, S., Morgan, K., Tam,
620 W., Paktinat, M., Okabe, R., *et al.* (2010b). Musashi-2 regulates normal hematopoiesis and
621 promotes aggressive myeloid leukemia. *Nat Med* 16, 903-908.

622 Komeno, Y., Yan, M., Matsuura, S., Lam, K., Lo, M.C., Huang, Y.J., Tenen, D.G., Downing,
623 J.R., and Zhang, D.E. (2014). Runx1 exon 6-related alternative splicing isoforms differentially
624 regulate hematopoiesis in mice. *Blood* 123, 3760-3769.

625 Kronke, J., Bullinger, L., Teleanu, V., Tschurtz, F., Gaidzik, V.I., Kuhn, M.W., Rucker, F.G.,
626 Holzmann, K., Paschka, P., Kapp-Schworer, S., *et al.* (2013). Clonal evolution in relapsed
627 NPM1-mutated acute myeloid leukemia. *Blood* 122, 100-108.

628 Minuesa, G., Albanese, S.K., Xie, W., Kazansky, Y., Worroll, D., Chow, A., Schurer, A., Park,
629 S.M., Rotsides, C.Z., Taggart, J., *et al.* (2019). Small-molecule targeting of MUSASHI RNA-
630 binding activity in acute myeloid leukemia. *Nat Commun* 10, 2691.

631 Miyoshi, H., Ohira, M., Shimizu, K., Mitani, K., Hirai, H., Imai, T., Yokoyama, K., Soeda, E., and
632 Ohki, M. (1995). Alternative splicing and genomic structure of the AML1 gene involved in acute
633 myeloid leukemia. *Nucleic acids research* 23, 2762-2769.

634 Naviaux, R.K., Costanzi, E., Haas, M., and Verma, I.M. (1996). The pCL vector system: rapid
635 production of helper-free, high-titer, recombinant retroviruses. *J Virol* 70, 5701-5705.

636 Novershtern, N., Subramanian, A., Lawton, L.N., Mak, R.H., Haining, W.N., McConkey, M.E.,
637 Habib, N., Yosef, N., Chang, C.Y., Shay, T., *et al.* (2011). Densely interconnected transcriptional
638 circuits control cell states in human hematopoiesis. *Cell* 144, 296-309.

639 Osato, M. (2004). Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
640 *Oncogene* 23, 4284-4296.

641 Osato, M., Asou, N., Abdalla, E., Hoshino, K., Yamasaki, H., Okubo, T., Suzushima, H.,
642 Takatsuki, K., Kanno, T., Shigesada, K., *et al.* (1999). Biallelic and heterozygous point
643 mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic
644 leukemias. *Blood* 93, 1817-1824.

645 Papaemmanuil, E., Cazzola, M., Boulton, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti,
646 A., Wainscoat, J.S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., *et al.* (2011). Somatic
647 SF3B1 mutation in myelodysplasia with ring sideroblasts. *N Engl J Med* 365, 1384-1395.

648 Papaemmanuil, E., Dohner, H., and Campbell, P.J. (2016). Genomic Classification in Acute
649 Myeloid Leukemia. *N Engl J Med* 375, 900-901.

650 Peniket, A., Wainscoat, J., Side, L., Daly, S., Kusec, R., Buck, G., Wheatley, K., Walker, H.,
651 Chatters, S., Harrison, C., *et al.* (2005). Del (9q) AML: clinical and cytological characteristics
652 and prognostic implications. *British journal of haematology* 129, 210-220.

653 Perl, A.E., Martinelli, G., Cortes, J.E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P.,
654 Baer, M.R., Larson, R.A., Ustun, C., *et al.* (2019). Gilteritinib or Chemotherapy for Relapsed or
655 Refractory FLT3-Mutated AML. *N Engl J Med* 381, 1728-1740.

656 Pimentel, H., Bray, N.L., Puente, S., Melsted, P., and Pachter, L. (2017). Differential analysis of
657 RNA-seq incorporating quantification uncertainty. *Nat Methods* 14, 687-690.

658 Saha, S., Murmu, K.C., Biswas, M., Chakraborty, S., Basu, J., Madhulika, S., Kolapalli, S.P.,
659 Chauhan, S., Sengupta, A., and Prasad, P. (2019). Transcriptomic Analysis Identifies RNA
660 Binding Proteins as Putative Regulators of Myelopoiesis and Leukemia. *Front Oncol* 9, 692.

661 Sanjabi, S., Williams, K.J., Sacconi, S., Zhou, L., Hoffmann, A., Ghosh, G., Gerondakis, S.,
662 Natoli, G., and Smale, S.T. (2005). A c-Rel subdomain responsible for enhanced DNA-binding
663 affinity and selective gene activation. *Genes & development* 19, 2138-2151.

664 Schmitt, C.A., Fridman, J.S., Yang, M., Baranov, E., Hoffman, R.M., and Lowe, S.W. (2002).
665 Dissecting p53 tumor suppressor functions in vivo. *Cancer cell* 1, 289-298.

666 Seiler, M., Yoshimi, A., Darman, R., Chan, B., Keaney, G., Thomas, M., Agrawal, A.A., Caleb,
667 B., Csibi, A., Sean, E., *et al.* (2018). H3B-8800, an orally available small-molecule splicing
668 modulator, induces lethality in spliceosome-mutant cancers. *Nat Med* 24, 497-504.

669 Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A.,
670 Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., *et al.* (2000). Karyotypic analysis predicts
671 outcome of preremission and postremission therapy in adult acute myeloid leukemia: a
672 Southwest Oncology Group/Eastern Cooperative Oncology Group Study. *Blood* 96, 4075-4083.

673 Stein, E.M., DiNardo, C.D., Fathi, A.T., Pollyea, D.A., Stone, R.M., Altman, J.K., Roboz, G.J.,
674 Patel, M.R., Collins, R., Flinn, I.W., *et al.* (2019). Molecular remission and response patterns in
675 patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. *Blood* 133, 676-687.

676 Stewart, S.A., Dykxhoorn, D.M., Palliser, D., Mizuno, H., Yu, E.Y., An, D.S., Sabatini, D.M.,
677 Chen, I.S., Hahn, W.C., Sharp, P.A., *et al.* (2003). Lentivirus-delivered stable gene silencing by
678 RNAi in primary cells. *RNA* 9, 493-501.

679 Stone, R.M., Mandrekar, S.J., Sanford, B.L., Laumann, K., Geyer, S., Bloomfield, C.D., Thiede,
680 C., Prior, T.W., Dohner, K., Marcucci, G., *et al.* (2017). Midostaurin plus Chemotherapy for
681 Acute Myeloid Leukemia with a FLT3 Mutation. *N Engl J Med* 377, 454-464.

682 Sugimura, R., Jha, D.K., Han, A., Soria-Valles, C., da Rocha, E.L., Lu, Y.F., Goettel, J.A.,
683 Serrao, E., Rowe, R.G., Malleshaiah, M., *et al.* (2017). Haematopoietic stem and progenitor
684 cells from human pluripotent stem cells. *Nature* 545, 432-438.

685 Sun, W., Zeng, J., Chang, J., Xue, Y., Zhang, Y., Pan, X., Zhou, Y., Lai, M., Bian, G., Zhou, Q.,
686 *et al.* (2020). RUNX1-205, a novel splice variant of the human RUNX1 gene, has blockage
687 effect on mesoderm-hemogenesis transition and promotion effect during the late stage of
688 hematopoiesis. *J Mol Cell Biol* 12, 386-396.

689 Sweetser, D.A., Peniket, A.J., Haaland, C., Blomberg, A.A., Zhang, Y., Zaidi, S.T., Dayyani, F.,
690 Zhao, Z., Heerema, N.A., Boulton, J., *et al.* (2005). Delineation of the minimal commonly

691 deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute
692 myeloid leukemia. *Genes Chromosomes Cancer* 44, 279-291.

693 Tanaka, T., Tanaka, K., Ogawa, S., Kurokawa, M., Mitani, K., Nishida, J., Shibata, Y., Yazaki,
694 Y., and Hirai, H. (1995). An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid
695 cell differentiation and transcriptional activation antagonistically by two alternative spliced forms.
696 *EMBO J* 14, 341-350.

697 Tyner, J.W., Tognon, C.E., Bottomly, D., Wilmot, B., Kurtz, S.E., Savage, S.L., Long, N.,
698 Schultz, A.R., Traer, E., Abel, M., *et al.* (2018). Functional genomic landscape of acute myeloid
699 leukaemia. *Nature* 562, 526-531.

700 Verhaak, R.G., Wouters, B.J., Erpelinck, C.A., Abbas, S., Beverloo, H.B., Lugthart, S.,
701 Lowenberg, B., Delwel, R., and Valk, P.J. (2009). Prediction of molecular subtypes in acute
702 myeloid leukemia based on gene expression profiling. *Haematologica* 94, 131-134.

703 Vu, L.P., Pickering, B.F., Cheng, Y., Zaccara, S., Nguyen, D., Minuesa, G., Chou, T., Chow, A.,
704 Saletore, Y., MacKay, M., *et al.* (2017). The N(6)-methyladenosine (m(6)A)-forming enzyme
705 METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. *Nat Med*
706 23, 1369-1376.

707 Wang, E., Lu, S.X., Pastore, A., Chen, X., Imig, J., Chun-Wei Lee, S., Hockemeyer, K.,
708 Ghebrechristos, Y.E., Yoshimi, A., Inoue, D., *et al.* (2019). Targeting an RNA-Binding Protein
709 Network in Acute Myeloid Leukemia. *Cancer cell* 35, 369-384 e367.

710 Wen, F., Shen, A., Shanas, R., Bhattacharyya, A., Lian, F., Hostetter, G., and Shi, J. (2010).
711 Higher expression of the heterogeneous nuclear ribonucleoprotein k in melanoma. *Ann Surg*
712 *Oncol* 17, 2619-2627.

713 Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-
714 Otsubo, A., Kon, A., Nagasaki, M., *et al.* (2011). Frequent pathway mutations of splicing
715 machinery in myelodysplasia. *Nature* 478, 64-69.

716 Zhang, D.E., Hetherington, C.J., Chen, H.M., and Tenen, D.G. (1994). The macrophage
717 transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating
718 factor receptor. *Molecular and cellular biology* 14, 373-381.

719 Zhao, X., Jankovic, V., Gural, A., Huang, G., Pardanani, A., Menendez, S., Zhang, J., Dunne,
720 R., Xiao, A., Erdjument-Bromage, H., *et al.* (2008). Methylation of RUNX1 by PRMT1 abrogates
721 SIN3A binding and potentiates its transcriptional activity. *Genes & development* 22, 640-653.

722 Zhou, R., Shanas, R., Nelson, M.A., Bhattacharyya, A., and Shi, J. (2010). Increased
723 expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its
724 association with the mutant p53. *International journal of cancer* 126, 395-404.

725 Zuber, J., Radtke, I., Pardee, T.S., Zhao, Z., Rappaport, A.R., Luo, W., McCurrach, M.E., Yang,
726 M.M., Dolan, M.E., Kogan, S.C., *et al.* (2009). Mouse models of human AML accurately predict
727 chemotherapy response. *Genes & development* 23, 877-889.

728

729

Figure legends

Figure 1: hnRNP K expression in *de novo* AML. (A) Relative hnRNP K protein expression as quantified by RPPA. CD34+ cells from healthy human donor bone marrows (n=10) are indicated in black. Cells from bone marrows of patients with AML (n=205) are shown in red. (C) Overall survival of AML patients with either high hnRNP K protein expression as determined by RPPA (red; n=45) or normal/low hnRNP K expression (blue; n=160). Data is publicly available at www.leukemiaatlas.org.

Figure 2: hnRNP K overexpression in murine HSPCs. (A) Western blot showing hnRNP K protein levels in HSPCs infected with empty vector or hnRNP K plasmids. (B) Representative brightfield images of colonies from HSPCs infected with empty vector or hnRNP K plasmid. Scale bar represents 500 μ m. (C) Bar graph quantitating the number of colonies per well in HSPCs infected with empty vector (n=14) and hnRNP K plasmids (n=10). (D) Flow cytometry analysis of HSPCs infected with empty vector and hnRNP K plasmids. (E) Bar graph quantitating the percentage of Gr1+CD11b+ and c-kit+Sca-1+ cells in HSPCs infected with empty vector (n=4) and hnRNP K plasmid (n=4).

Figure 3: Phenotypes observed in mice transplanted with hnRNP K overexpressing HSPCs. (A) Kaplan-Meier curves indicating survival of mice transplanted with HSPCs infected with an empty vector (n=13) and hnRNP K overexpression plasmid (n=22). Expression levels for hnRNP K in the HSPCs is depicted in the inset. (B) Percent donor cells in the peripheral blood of mice transplanted with HSPCs. (C) H&E staining in bone marrow samples obtained from mice transplanted with empty vector and hnRNP K overexpressing HSPCs. The scale bar represents 50 μ m. (D) Representative photos of spleens from mice transplanted with empty vector and

hnRNP K overexpressing HSPCs. (E) Bar graph depicting spleen weights from mice transplanted with empty vector (n=12) and hnRNP K overexpressing (n=21) HSPCs. (F) H&E and immunohistochemical analyses for hnRNP K in spleen samples from mice transplanted with empty vector or hnRNP K overexpressing HSPCs. The scale bar represents 200 μ m.

Figure 4: Mechanistic basis for the oncogenicity of hnRNP K. (A) Volcano plot indicating alternatively spliced transcripts in HSPCs infected with empty vector (n=3) and hnRNP K plasmid (n=3). (B) Graph depicting differentially spliced transcripts in HSPCs infected with hnRNP K plasmid compared to empty vector, subsetted by causal implication in heme malignancies. (C) Graph depicting hnRNP K-associated transcripts, as determined by fRIP analysis, subsetted by causal implication in heme malignancies. The fRIP-Seq experiments were previously performed in the laboratory in triplicate in OCI-AML3 cells. (D) Identification of putative hnRNP K binding sites in the human and murine *RUNX1* transcripts using a previously generated computer algorithm. (E & F) Fluorescence anisotropy binding curves for purified full-length hnRNP K with FAM-labeled human and murine RUNX intron 5-6 wild-type and mutant oligos. Binding assays were performed in triplicate.

Figure 5: Assessing hnRNP K's impact on *RUNX1* alternative splicing. (A) RT-PCR based splicing analysis for *RUNX1* full-length and Δ Ex6 isoforms in HSPCs infected with empty vector or hnRNP K plasmid. *Gapdh* was used as a loading control. (B) RT-PCR splicing analysis for *RUNX1* full-length and Δ Ex6 isoforms in 293T cells followed by Sanger sequencing to confirm the sequences of the splice isoforms under study. (C) RT-PCR based splicing analysis for *RUNX1* full-length and Δ Ex6 isoforms in peripheral blood and bone marrow cells obtained from healthy controls or AML patients. *PPIA* was used as a loading control. (D) RT-PCR based splicing analysis for *RUNX1* full-length and Δ Ex6 isoforms in stable cell lines (K562, OCI-AML3,

THP1) that overexpress hnRNP K. *PPIA* was used as a loading control. (E) RT-PCR based splicing analysis for *RUNX1* full-length and Δ Ex6 isoforms in K562 stable cell lines with shRNA-mediated hnRNP K knockdown. One shRNA targets the hnRNP K CDS (Ex10) and two hairpins target the 3'-UTR (Ex16-1 and Ex16-2). *PPIA* was used as a loading control. (F) RT-PCR based splicing analysis for *RUNX1* full-length and Δ Ex6 isoforms in K562 stable cell lines with shRNA-mediated hnRNP K knockdown rescued with hnRNP K overexpression. *PPIA* was used as a loading control.

Figure 6: Functional relevance of the *RUNX* Δ Ex6 splice isoform. (A) Immunoblot for RUNX1 following a cycloheximide chase experiment in 293T cells that stably express *RUNX1* full-length or RUNX Δ Ex6. HSP90 serves as the loading control. (B) Immunoblot for RUNX1 following cycloheximide+MG132 treatment in 293T cells that stably express *RUNX1* full-length or RUNX Δ Ex6. HSP90 serves as the loading control. (C) Luciferase-based reporter assay to assess transactivation from a CSF-1R promoter reporter in 293T cells. The experiment was independently done three times in triplicate. (D) Bar graph representing number of colonies formed per well for HSPCs infected with empty vector (n=7), *RUNX1* full-length (n=4) or RUNX Δ Ex6 (n=4) plasmid. (E) RT-PCR based splicing assay (in 293T cells) to determine the impact of different hnRNP K protein domains in regulating RUNX1 alternative splicing. (F) Bar graph representing number of colonies formed per well for HSPCs infected with empty vector (n=7), hnRNP K (n=7) or hnRNP K Δ KH3 (n=3) plasmid.